Pericardial Effusion Secondary to Nilotinib in an Elderly Patient With Chronic Myelogenous Leukemia

Authors

Geetika Arora, Internal Medicine, Mount Sinai Beth Israel/Icahn School of Medicine at Mount Sinai, New York City, USA.
Paulus Adinugraha, Internal Medicine, Mount Sinai Beth Israel/Icahn School of Medicine at Mount Sinai, New York City, USA.
Amna Aijaz, Internal Medicine/Public Health, George Washington University, Washington, D.C., USA.
Alvaro Vargas Pelaez, Cardiology, Mount Sinai Beth Israel/Icahn School of Medicine at Mount Sinai, New York City, USA.
Maurice Rachko, Cardiology, Mount Sinai Beth Israel/Icahn School of Medicine at Mount Sinai, New York City, USA.

Document Type

Journal Article

Publication Date

4-1-2022

Journal

Cureus

Volume

14

Issue

4

DOI

10.7759/cureus.23855

Keywords

cardiac tamponade; nilotinib; pericardial effusion; serositis; tyrosine kinase inhibitors (tki)

Abstract

Tyrosine kinase inhibitors (TKIs) are the first-line treatment for patients with chronic myelogenous leukemia (CML). Serositis, including pleural and pericardial effusions, is a frequent adverse event with some TKIs while less frequent with others. We present a case of a 76-year-old woman with CML on nilotinib who presented with progressive fatigue and was eventually found to have cardiac tamponade from a large pericardial effusion attributed to nilotinib. The patient required urgent therapeutic pericardiocentesis and switching of TKIs from nilotinib to bosutinib.

APA Citation

Arora, Geetika; Adinugraha, Paulus; Aijaz, Amna; Vargas Pelaez, Alvaro; and Rachko, Maurice, "Pericardial Effusion Secondary to Nilotinib in an Elderly Patient With Chronic Myelogenous Leukemia" (2022). GW Authored Works. Paper 824.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/824

Department

Public Health Student Works